<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15365">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02906852</url>
  </required_header>
  <id_info>
    <org_study_id>INI001</org_study_id>
    <nct_id>NCT02906852</nct_id>
  </id_info>
  <brief_title>Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing</brief_title>
  <official_title>A Prospective Study to Evaluate the Performance of Inivata Liquid Biopsy Compared With Standard Tissue Biopsy for Detection of Genomic Alterations in Patients With Advanced Non Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inivata</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vector Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Inivata</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the performance of Inivata liquid biopsy analysis
      compared with standard tissue biopsy analysis for detection of genomic alterations in
      patients with advanced lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate the performance of Inivata liquid biopsy analysis
      compared with standard tissue biopsy analysis for detection of genomic alterations in
      patients with advanced lung cancer. Once selected for the study and with full informed
      consent, patients will have a blood draw to allow the detection of cancer-related genomic
      alterations that are detectable within the blood sample. These results will be compared to
      results obtained from genomic profiling via standard tissue biopsy taken as part of routine
      care to help determine whether such 'liquid biopsies' can be used to guide treatments in
      future patients. The results of the liquid biopsy will not be used to guide treatment
      decisions in study participants.

      In addition there is data-collection of treatments received for non small cell lung cancer
      and the response to these treatments during the first 6 months post tissue and blood
      analysis, though no additional visits or procedures are required for the patient beyond the
      initial blood draw.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance in the detection of molecular abnormalities using Inivata's liquid biopsy panel with detection using standard of care tissue biopsy analysis</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection: sensitivity and specificity of molecular abnormalities using Inivata liquid biopsy panel relative to standard of care tissue biopsy analysis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of NSCLC patients eligible for targeted therapy based on liquid biopsy analysis as an evaluation of feasibility molecular stratification, compared to standard of care alone</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) rate over 6 months</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) rate over 6 months</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Relationship of clinical response to therapy with mutation allele frequency (MAF) cutoff in Inivata liquid biopsy assay</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A 40ml blood sample will be taken, from which Plasma and ultimately DNA/RNA will be
      prepared.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female patients aged 18 years and over diagnosed with stage IIIb/IV non-squamous
        NSCLC, who are intended to initiate first-line treatment according to standard guidelines,
        or having recently progressed on first-line EGFR or ALK directed therapy and being
        considered for further therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written, signed and dated informed consent to participate in the study must be given
             by the patient in accordance with 21 CFR Part 312, the International Conference on
             Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6, and applicable
             regulations, before completing any study-related procedures.

          -  Male and female patients aged 18 years and over diagnosed with stage IIIb/IV
             non-squamous NSCLC.

          -  Patients intended to initiate first-line treatment according to standard guidelines,
             or having recently progressed on first-line EGFR or ALK directed therapy and being
             considered for further therapy. If enrolled in a treatment clinical trial, patients
             may enroll in this study if all eligibility criteria are met.

          -  Patients who plan to have or have had a recent tumor tissue biopsy taken for
             molecular profiling as part of their standard of care.

          -  Patient must understand and be able, willing and likely to fully comply with all
             study procedures and restrictions.

        Exclusion Criteria:

          -  Patients who have received any approved or experimental cancer therapy since their
             most recent NSCLC tissue biopsy.

          -  Patients who have any other prior metastatic or current second primary cancer.

          -  Patient who has a severe acute or chronic medical or psychiatric condition or
             laboratory abnormality that may increase the risk associated with study participation
             or may interfere with the interpretation of study results and, in the judgment of the
             Investigator, would make the patient inappropriate for entry into this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramaswamy Govindan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Levine Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clive Morris, MD</last_name>
    <role>Study Director</role>
    <affiliation>Inivata</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Molly Bur</last_name>
    <phone>1-901-574-4601</phone>
    <email>mbur@vectoroncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Cole</last_name>
    <phone>1-901-435-5571</phone>
    <email>scole@vectoroncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ross Camidge, MD</last_name>
      <phone>303-724-8652</phone>
      <email>ross.camidge@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brittany Kling</last_name>
      <phone>780-848-0498</phone>
      <email>brittany.kling@ucdenver.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Eastern CT Hematology Oncology</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Slater, MD</last_name>
      <phone>860-886-8362</phone>
      <email>drslater@echoct.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Services Inc</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Guarino, MD</last_name>
      <phone>302-623-4639</phone>
      <email>mguarino@cbg.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Z Drew, MD</last_name>
      <phone>954-267-7730</phone>
      <email>david.drew@holy-cross.com</email>
    </contact>
    <contact_backup>
      <last_name>Tia Morgan</last_name>
      <phone>954-229-8528</phone>
      <email>Tia.Morgan@holy-cross.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mid-Florida Hematology and Oncology Centers</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santosh Nair, MD</last_name>
      <phone>386-774-1223</phone>
      <email>drsmnair@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Rina Ashby</last_name>
      <phone>386-774-1223</phone>
      <email>rina@clorene.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Edward M Kaplan, MD &amp; Associates</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Kaplan, MD</last_name>
      <phone>847-675-3900</phone>
      <email>ekapla@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Marsha Weller</last_name>
      <phone>847-675-3900</phone>
      <email>mregwell@yahoo.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Clinical Research Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmood Hashmi, MD</last_name>
      <email>mhashmi@stormontvail.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christus Cancer Treatment Center</name>
      <address>
        <city>Sherveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Boniol, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jennifer Powell</last_name>
      <phone>318-681-6007</phone>
      <email>Jennifer.powell@christushealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Berkshire Hematology Oncology Services</name>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <zip>01201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trevor Bayliss, MD</last_name>
      <phone>413-496-8205</phone>
      <email>tbayliss@bhs1.org</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Ziemek</last_name>
      <phone>413 496-8205</phone>
      <email>jziemek@bhs1.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Jackson Oncology Associates, PLLC</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manu Patel, MD</last_name>
      <phone>601-974-5447</phone>
      <email>mpatel@mbhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Teresa Davis</last_name>
      <phone>1-601-974-5447</phone>
      <email>teresadavis@mbhs.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Northshore Hematology Oncology</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Chu, MD</last_name>
      <email>dchu@nshoa.com</email>
    </contact>
    <contact_backup>
      <last_name>Don Marx</last_name>
      <email>dmarx@nshoa.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Northern Westchester Hospital Association</name>
      <address>
        <city>Kisco</city>
        <state>New York</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Goldberg, MD</last_name>
      <phone>914-666-1366</phone>
      <email>jgoldberg@cmmedical.com</email>
    </contact>
    <contact_backup>
      <last_name>Asha Mellor</last_name>
      <phone>914-666-1366</phone>
      <email>amellor@nwhc.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Pinehurst Medical Clinic</name>
      <address>
        <city>Pinehurst</city>
        <state>North Carolina</state>
        <zip>28374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Pritchett, MD</last_name>
      <phone>910-235-3144</phone>
      <email>Mpritchett@pinehurstmedical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trinity Cancer Center</name>
      <address>
        <city>Minot</city>
        <state>North Dakota</state>
        <zip>58701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Makoni, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Pam Brewer</last_name>
      <phone>701-857-3174</phone>
      <email>pamela.brewer@trinityheatlh.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Gettysburg Cancer Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satish Shah, MD</last_name>
      <phone>717-334-4033</phone>
      <email>drshah@gettysburgoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Vanessa Hardman</last_name>
      <phone>717-334-4033</phone>
      <email>vhardman@gettysburgoncology.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Carolina Blood and Cancer Care</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sashi Naidu, MD</last_name>
      <phone>803-329-7772</phone>
      <email>snaidu@cbcca.net</email>
    </contact>
    <contact_backup>
      <last_name>Niyati Nathwani</last_name>
      <email>nanathwani@cbcca.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Schwartzberg, MD</last_name>
      <phone>901-683-0055</phone>
      <email>lschwartzberg@westclinic.com</email>
    </contact>
    <contact_backup>
      <last_name>Kathy Schwend</last_name>
      <phone>901-683-0055</phone>
      <email>kschwend@westclinic.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tennessee Cancer Specialists</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russell F DeVore, MD</last_name>
      <phone>865-934-2670</phone>
      <email>rdevore@biomed-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Spann Clinic Oncology</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78412</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aftab Mahmood</last_name>
      <phone>361-993-3456</phone>
      <email>aftab.mahmood@thomasspann.com</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Fonseca</last_name>
      <phone>1-361-993-3456</phone>
      <email>lisa.fonseca@thomasspann.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Providence Regional Medical Center</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Lukas, MD</last_name>
      <email>jlukas@everettclinic.com</email>
    </contact>
    <contact_backup>
      <last_name>Alyssa Shery</last_name>
      <phone>425-297-5577</phone>
      <email>Alyssa.Sherry@providence.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Washington (Swedish General)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard West, MD</last_name>
      <email>Howard.West@swedish.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Rose, MD</last_name>
      <email>Rose_research@nwmsonline.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>September 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
